BioVaxys公司将25K美元的债务加利息转换为148 468股,并给予内部人550K股票期权。 BioVaxys converted $25K in debt plus interest into 148,468 shares and granted 550K stock options to insiders.

BioVaxys Technology Corp. 将25 000美元的可兑换债券加上239.73美元的应计利息转换成148 468个共同股份,每股0.17美元。 BioVaxys Technology Corp. converted $25,000 in convertible debentures plus $239.73 in accrued interest into 148,468 common shares at $0.17 per share after a holder’s notice. 该公司还给予内部人员和关键人员550 000份股票期权,在2030年10月20日之前按每股0.25美元计算,并逐步发放。 The company also granted 550,000 stock options to insiders and key personnel, exercisable at $0.25 per share until October 20, 2030, with gradual vesting. 由于内部参与有限,这些交易不受加拿大某些条例的约束。 The transactions were exempt from certain Canadian regulations due to limited insider involvement. 该公司位于不列颠哥伦比亚省,利用DPXTM和HapTenix平台开发癌症、传染病和过敏的免疫疗法。 The firm, based in British Columbia, develops immunotherapies for cancer, infectious diseases, and allergies using its DPX™ and HapTenix© platforms. 其主要候选人Maveropepimimut-S正在第二阶段b对高级淋巴瘤和卵巢癌进行试验,显示出安全和免疫反应。 Its lead candidate, maveropepimut-S, is in Phase IIb trials for advanced lymphoma and ovarian cancer, demonstrating safety and immune response. 其他管道项目包括双重目标疗法、花生过敏治疗和个性化癌症疫苗。 Other pipeline projects include dual-targeted therapies, peanut allergy treatments, and personalized cancer vaccines. 所有证券均需经监管批准,不在美国登记出售。 All securities are subject to regulatory approval and are not registered for sale in the U.S.